Display options
Cite
Kubat NJ, Moffett J, Fray LM. Effect of pulsed electromagnetic field treatment on programmed resolution of inflammation pathway markers in human cells in culture. J Inflamm Res. 2015;8:59-69doi: 10.2147/JIR.S78631.
Kubat, N. J., Moffett, J., & Fray, L. M. (2015). Effect of pulsed electromagnetic field treatment on programmed resolution of inflammation pathway markers in human cells in culture. Journal of inflammation research, 859-69. https://doi.org/10.2147/JIR.S78631
Kubat, Nicole J, et al. "Effect of pulsed electromagnetic field treatment on programmed resolution of inflammation pathway markers in human cells in culture." Journal of inflammation research vol. 8 (2015): 59-69. doi: https://doi.org/10.2147/JIR.S78631
Kubat NJ, Moffett J, Fray LM. Effect of pulsed electromagnetic field treatment on programmed resolution of inflammation pathway markers in human cells in culture. J Inflamm Res. 2015 Feb 23;8:59-69. doi: 10.2147/JIR.S78631. eCollection 2015. PMID: 25759595; PMCID: PMC4346366.
Copy Download .nbib Format: NLM
Share it on

J Inflamm Res. 2015 Feb 23;8:59-69. doi: 10.2147/JIR.S78631. eCollection 2015.

Effect of pulsed electromagnetic field treatment on programmed resolution of inflammation pathway markers in human cells in culture.

Journal of inflammation research

Nicole J Kubat, John Moffett, Linley M Fray

Affiliations

  1. Nicole Kubat Consulting, Pasadena, CA, USA.
  2. Life Science Department, Regenesis Biomedical, Inc., Scottsdale, AZ, USA.

PMID: 25759595 PMCID: PMC4346366 DOI: 10.2147/JIR.S78631

Abstract

Inflammation is a complex process involving distinct but overlapping biochemical and molecular events that are highly regulated. Pulsed electromagnetic field (PEMF) therapy is increasingly used to treat pain and edema associated with inflammation following surgery involving soft tissue. However, the molecular and cellular effects of PEMF therapy on pathways involved in the resolution of inflammation are poorly understood. Using cell culture lines relevant to trauma-induced inflammation of the skin (human dermal fibroblasts, human epidermal keratinocytes, and human mononuclear cells), we investigated the effect of PEMF on gene expression involved in the acute and resolution phases of inflammation. We found that PEMF treatment was followed by changes in the relative amount of messenger (m)RNAs encoding enzymes involved in heme catabolism and removal of reactive oxygen species, including an increase in heme oxygenase 1 and superoxide dismutase 3 mRNAs, in all cell types examined 2 hours after PEMF treatment. A relative increase in mRNAs encoding enzymes involved in lipid mediator biosynthesis was also observed, including an increase in arachidonate 12- and 15-lipoxygenase mRNAs in dermal fibroblasts and epidermal keratinocytes, respectively. The relative amount of both of these lipoxygenase mRNAs was elevated in mononuclear cells following PEMF treatment relative to nontreated cells. PEMF treatment was also followed by changes in the mRNA levels of several cytokines. A decrease in the relative amount of interleukin 1 beta mRNA was observed in mononuclear cells, similar to that previously reported for epidermal keratinocytes and dermal fibroblasts. Based on our results, we propose a model in which PEMF therapy may promote chronic inflammation resolution by mediating gene expression changes important for inhibiting and resolving inflammation.

Keywords: acute inflammation; cytokines; eicosanoids; heme oxygenase; lipid mediators; reactive oxygen species; resolution phase; resolvins

References

  1. Pharmacology. 2011;87(1-2):49-55 - PubMed
  2. Mini Rev Med Chem. 2001 May;1(1):5-16 - PubMed
  3. Biochim Biophys Acta. 2015 Apr;1851(4):469-84 - PubMed
  4. J Pharmacol Exp Ther. 1999 Oct;291(1):416-23 - PubMed
  5. Int Rev Immunol. 2013 Jun;32(3):249-70 - PubMed
  6. Front Pharmacol. 2012 Jul 19;3:119 - PubMed
  7. Cell Metab. 2014 Jan 7;19(1):21-36 - PubMed
  8. Cytokine. 2008 Sep;43(3):380-90 - PubMed
  9. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16093-8 - PubMed
  10. Biochim Biophys Acta. 2014 Sep;1840(9):2709-29 - PubMed
  11. Immunol Rev. 2008 Dec;226:205-18 - PubMed
  12. Nature. 2014 Jun 5;510(7503):92-101 - PubMed
  13. Methods. 2001 Dec;25(4):402-8 - PubMed
  14. Ann Surg. 2012 Mar;255(3):457-67 - PubMed
  15. Pharmacol Rev. 2004 Sep;56(3):387-437 - PubMed
  16. Br Med Bull. 1995 Apr;51(2):368-84 - PubMed
  17. Blood. 2001 Sep 15;98 (6):1802-11 - PubMed
  18. Nature. 2008 Jul 24;454(7203):428-35 - PubMed
  19. Cell. 2009 Oct 16;139(2):267-84 - PubMed
  20. Nat Immunol. 2001 Jul;2(7):612-9 - PubMed
  21. Aesthetic Plast Surg. 2012 Apr;36(2):458-63 - PubMed
  22. Bioelectrochem Bioenerg. 1999 Feb;48(1):27-34 - PubMed
  23. Nat Rev Immunol. 2013 Jan;13(1):59-66 - PubMed
  24. Biochim Biophys Acta. 2015 Apr;1851(4):397-413 - PubMed
  25. J Biomed Sci. 2011 Nov 30;18:90 - PubMed
  26. Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36 - PubMed
  27. Annu Rev Pharmacol Toxicol. 2010;50:323-54 - PubMed
  28. J Allergy Clin Immunol. 2008 May;121(5):1108-11 - PubMed
  29. J Lipids. 2013;2013:710290 - PubMed
  30. Semin Immunol. 2012 Dec;24(6):384-92 - PubMed
  31. J Pharmacol Sci. 2014;124(3):307-12 - PubMed
  32. Front Pharmacol. 2012 Mar 16;3:47 - PubMed
  33. Blood. 2003 Jul 15;102(2):521-8 - PubMed
  34. Biochim Biophys Acta. 2015 Apr;1851(4):331-9 - PubMed
  35. Cell. 2010 Mar 19;140(6):771-6 - PubMed
  36. J Pain Res. 2012;5:347-57 - PubMed
  37. Electromagn Biol Med. 2011 Mar;30(1):21-45 - PubMed
  38. Life Sci. 2007 Jun 6;80(26):2403-10 - PubMed
  39. Thromb Haemost. 1997 Jul;78(1):302-5 - PubMed
  40. J Physiol Pharmacol. 2013 Aug;64(4):409-21 - PubMed
  41. Pain Physician. 2014 Mar-Apr;17(2):E175-211 - PubMed
  42. Aesthetic Plast Surg. 2008 Jul;32(4):660-6 - PubMed
  43. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20647-8 - PubMed
  44. Trends Pharmacol Sci. 2013 Jul;34(7):413-23 - PubMed
  45. Electromagn Biol Med. 2013 Mar;32(1):59-69 - PubMed
  46. Nat Med. 2000 Apr;6(4):422-8 - PubMed
  47. J Inflamm Res. 2013;6:45-51 - PubMed
  48. Arthritis Rheum. 1981 Sep;24(9):1151-8 - PubMed
  49. J Clin Invest. 1995 Apr;95(4):1669-75 - PubMed
  50. Fibrogenesis Tissue Repair. 2008 Oct 13;1(1):5 - PubMed
  51. Anesth Analg. 2003 Aug;97(2):534-40, table of contents - PubMed
  52. Prog Lipid Res. 2011 Jan;50(1):75-88 - PubMed
  53. J Investig Dermatol Symp Proc. 2006 Sep;11(1):106-11 - PubMed
  54. J Immunol. 2012 Jun 1;188(11):5734-40 - PubMed
  55. J Pain Res. 2013 Nov 21;6:803-14 - PubMed
  56. J Rheumatol Suppl. 1999 May;57:7-15 - PubMed
  57. Immunity. 2014 Mar 20;40(3):315-27 - PubMed
  58. Cell. 2010 Mar 19;140(6):871-82 - PubMed
  59. Antioxid Redox Signal. 2014 Mar 1;20(7):1126-67 - PubMed
  60. J Exp Med. 2009 Jan 16;206(1):15-23 - PubMed
  61. Pharmacol Rev. 2003 Sep;55(3):551-71 - PubMed
  62. Trends Neurosci. 2011 Nov;34(11):599-609 - PubMed
  63. Annu Rev Immunol. 2007;25:101-37 - PubMed
  64. Curr Protoc Immunol. 2011 Nov;Chapter 14:Unit 14.26 - PubMed
  65. Nat Rev Immunol. 2008 May;8(5):349-61 - PubMed
  66. Bioelectromagnetics. 2010 Dec;31(8):603-12 - PubMed
  67. Eur J Pharmacol. 1994 Aug 22;261(3):237-47 - PubMed
  68. Plast Reconstr Surg. 2010 Jun;125(6):1620-9 - PubMed
  69. Nat Rev Immunol. 2009 Oct;9(10):692-703 - PubMed
  70. Nat Med. 2010 May;16(5):592-7, 1p following 597 - PubMed
  71. Science. 2015 Jan 2;347(6217):18-21 - PubMed
  72. Cleve Clin J Med. 1999 Jun;66(6):367-74 - PubMed
  73. Pharmacol Rep. 2007 May-Jun;59(3):247-58 - PubMed
  74. Electromagn Biol Med. 2013 Jun;32(2):123-36 - PubMed
  75. PLoS One. 2013;8(1):e54376 - PubMed
  76. Int Med Case Rep J. 2014 Dec 31;8:13-22 - PubMed
  77. J Pharm Pharmacol. 2009 Nov;61(11):1435-48 - PubMed
  78. Brain Res Rev. 2009 Apr;60(1):90-113 - PubMed
  79. Annu Rev Pathol. 2008;3:279-312 - PubMed
  80. Front Pharmacol. 2014 May 27;5:115 - PubMed
  81. Am J Pathol. 2010 Oct;177(4):1576-91 - PubMed
  82. Blood. 2000 Oct 1;96(7):2584-91 - PubMed
  83. Inflamm Res. 2011 Dec;60(12 ):1083-92 - PubMed

Publication Types